Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study

  • Luis Manuel Entrenas Costa, Francisco Casas-Maldonado, José Gregorio Soto Campos, Alicia Padilla-Galo, Alberto Levy, Francisco Javier Álvarez Gutiérrez, Ana P. Gómez-Bastero Fernández, Concepción Morales-García, Rocío Gallego Domínguez, Gustavo Villegas Sánchez, Luis Mateos Caballero, Antonio Pereira-Vega, Cayo García Polo, Gerardo Pérez Chica, Juan José Martín Villasclaras
  • PharmacoEconomics - Open, January 2019, Springer Science + Business Media
  • DOI: 10.1007/s41669-019-0117-4

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

http://dx.doi.org/10.1007/s41669-019-0117-4

The following have contributed to this page: Dr francisco javier fj alvarez gutiérrez and Dr Luis M Entrenas Costa